Genetic variations of melatonin receptor type 1a are associated with the clinicopathologic development of urothelial cell carcinoma

Yung Wei Lin, Shian Shiang Wang, Yu Ching Wen, Min Che Tung, Liang Ming Lee, Shun Fa Yang, Ming Hsien Chien

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Melatonin counteracts tumor occurrence and tumor cell progression in several cancer types in vitro and in vivo. It acts predominantly through its melatonin receptor type 1A (MTNR1A), and genetic variations of MTNR1A affect the susceptibility several diseases and cancer. The purpose of this study was to explore the effect of MTNR1A gene polymorphisms on the susceptibility to and clinicopathological characteristics of urothelial cell carcinoma (UCC). We recruited 272 patients with UCC and 272 normal controls to analyze three common single-nucleotide polymorphisms (SNPs) (rs2119882, rs13140012, and rs6553010) of MTNR1A related to cancer risk and clinicopathological relevance according to a TaqMan-based real-time polymerase chain reaction (PCR). We found that these three SNPs of MTNR1A were not associated with UCC susceptibility. However, patients with UCC who had at least one G allele of MTNR1A rs6553010 (in intron 1) were at higher risk (1.768-fold, 95% confidence interval: 1.068~1.849) of developing an invasive stage (p < 0.026), compared to those patients with AA homozygotes. In conclusion, polymorphic genotypes of rs6553010 of MTNR1A might contribute to the ability to predict aggressive phenotypes of UCC. This is the first study to provide insights into risk factors associated with intronic MTNR1A variants in the clinicopathologic development of UCC in Taiwan.

Original languageEnglish
Pages (from-to)1130-1135
Number of pages6
JournalInternational Journal of Medical Sciences
Volume14
Issue number11
DOIs
Publication statusPublished - Sep 4 2017

Fingerprint

Melatonin Receptors
Carcinoma
Neoplasms
Single Nucleotide Polymorphism
Disease Susceptibility
Homozygote
Melatonin
Taiwan
Introns
Real-Time Polymerase Chain Reaction
Alleles
Genotype
Confidence Intervals
Phenotype

Keywords

  • Clinicopathologic development
  • Melatonin receptor type 1A
  • Single-nucleotide polymorphisms
  • Urothelial cell carcinoma

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic variations of melatonin receptor type 1a are associated with the clinicopathologic development of urothelial cell carcinoma. / Lin, Yung Wei; Wang, Shian Shiang; Wen, Yu Ching; Tung, Min Che; Lee, Liang Ming; Yang, Shun Fa; Chien, Ming Hsien.

In: International Journal of Medical Sciences, Vol. 14, No. 11, 04.09.2017, p. 1130-1135.

Research output: Contribution to journalArticle

@article{32ead9c2661f469680fdbb6f147f7c74,
title = "Genetic variations of melatonin receptor type 1a are associated with the clinicopathologic development of urothelial cell carcinoma",
abstract = "Melatonin counteracts tumor occurrence and tumor cell progression in several cancer types in vitro and in vivo. It acts predominantly through its melatonin receptor type 1A (MTNR1A), and genetic variations of MTNR1A affect the susceptibility several diseases and cancer. The purpose of this study was to explore the effect of MTNR1A gene polymorphisms on the susceptibility to and clinicopathological characteristics of urothelial cell carcinoma (UCC). We recruited 272 patients with UCC and 272 normal controls to analyze three common single-nucleotide polymorphisms (SNPs) (rs2119882, rs13140012, and rs6553010) of MTNR1A related to cancer risk and clinicopathological relevance according to a TaqMan-based real-time polymerase chain reaction (PCR). We found that these three SNPs of MTNR1A were not associated with UCC susceptibility. However, patients with UCC who had at least one G allele of MTNR1A rs6553010 (in intron 1) were at higher risk (1.768-fold, 95{\%} confidence interval: 1.068~1.849) of developing an invasive stage (p < 0.026), compared to those patients with AA homozygotes. In conclusion, polymorphic genotypes of rs6553010 of MTNR1A might contribute to the ability to predict aggressive phenotypes of UCC. This is the first study to provide insights into risk factors associated with intronic MTNR1A variants in the clinicopathologic development of UCC in Taiwan.",
keywords = "Clinicopathologic development, Melatonin receptor type 1A, Single-nucleotide polymorphisms, Urothelial cell carcinoma",
author = "Lin, {Yung Wei} and Wang, {Shian Shiang} and Wen, {Yu Ching} and Tung, {Min Che} and Lee, {Liang Ming} and Yang, {Shun Fa} and Chien, {Ming Hsien}",
year = "2017",
month = "9",
day = "4",
doi = "10.7150/ijms.20629",
language = "English",
volume = "14",
pages = "1130--1135",
journal = "International Journal of Medical Sciences",
issn = "1449-1907",
publisher = "Ivyspring International Publisher",
number = "11",

}

TY - JOUR

T1 - Genetic variations of melatonin receptor type 1a are associated with the clinicopathologic development of urothelial cell carcinoma

AU - Lin, Yung Wei

AU - Wang, Shian Shiang

AU - Wen, Yu Ching

AU - Tung, Min Che

AU - Lee, Liang Ming

AU - Yang, Shun Fa

AU - Chien, Ming Hsien

PY - 2017/9/4

Y1 - 2017/9/4

N2 - Melatonin counteracts tumor occurrence and tumor cell progression in several cancer types in vitro and in vivo. It acts predominantly through its melatonin receptor type 1A (MTNR1A), and genetic variations of MTNR1A affect the susceptibility several diseases and cancer. The purpose of this study was to explore the effect of MTNR1A gene polymorphisms on the susceptibility to and clinicopathological characteristics of urothelial cell carcinoma (UCC). We recruited 272 patients with UCC and 272 normal controls to analyze three common single-nucleotide polymorphisms (SNPs) (rs2119882, rs13140012, and rs6553010) of MTNR1A related to cancer risk and clinicopathological relevance according to a TaqMan-based real-time polymerase chain reaction (PCR). We found that these three SNPs of MTNR1A were not associated with UCC susceptibility. However, patients with UCC who had at least one G allele of MTNR1A rs6553010 (in intron 1) were at higher risk (1.768-fold, 95% confidence interval: 1.068~1.849) of developing an invasive stage (p < 0.026), compared to those patients with AA homozygotes. In conclusion, polymorphic genotypes of rs6553010 of MTNR1A might contribute to the ability to predict aggressive phenotypes of UCC. This is the first study to provide insights into risk factors associated with intronic MTNR1A variants in the clinicopathologic development of UCC in Taiwan.

AB - Melatonin counteracts tumor occurrence and tumor cell progression in several cancer types in vitro and in vivo. It acts predominantly through its melatonin receptor type 1A (MTNR1A), and genetic variations of MTNR1A affect the susceptibility several diseases and cancer. The purpose of this study was to explore the effect of MTNR1A gene polymorphisms on the susceptibility to and clinicopathological characteristics of urothelial cell carcinoma (UCC). We recruited 272 patients with UCC and 272 normal controls to analyze three common single-nucleotide polymorphisms (SNPs) (rs2119882, rs13140012, and rs6553010) of MTNR1A related to cancer risk and clinicopathological relevance according to a TaqMan-based real-time polymerase chain reaction (PCR). We found that these three SNPs of MTNR1A were not associated with UCC susceptibility. However, patients with UCC who had at least one G allele of MTNR1A rs6553010 (in intron 1) were at higher risk (1.768-fold, 95% confidence interval: 1.068~1.849) of developing an invasive stage (p < 0.026), compared to those patients with AA homozygotes. In conclusion, polymorphic genotypes of rs6553010 of MTNR1A might contribute to the ability to predict aggressive phenotypes of UCC. This is the first study to provide insights into risk factors associated with intronic MTNR1A variants in the clinicopathologic development of UCC in Taiwan.

KW - Clinicopathologic development

KW - Melatonin receptor type 1A

KW - Single-nucleotide polymorphisms

KW - Urothelial cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=85029654758&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029654758&partnerID=8YFLogxK

U2 - 10.7150/ijms.20629

DO - 10.7150/ijms.20629

M3 - Article

AN - SCOPUS:85029654758

VL - 14

SP - 1130

EP - 1135

JO - International Journal of Medical Sciences

JF - International Journal of Medical Sciences

SN - 1449-1907

IS - 11

ER -